WALTHAM, MA--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, disclosed for the first time preclinical data for IMGN779. The data were presented at the 19th Congress of the European Hematology Association (EHA) meeting in Milan, Italy (abstract# P802). IMGN779 is a novel, CD33-targeting, DNA-alkylating ADC that is a potential treatment for acute myeloid leukemia (AML).
Help employers find you! Check out all the jobs and post your resume.
